Abstract
Connective tissue remodeling is achieved by a complex process involving several cell types, a plethora of growth factors, cytokines, chemokines and turnover of extracellular matrix (ECM). The main enzymes that degrade ECM molecules are matrix metalloproteinases (MMPs) and their activities are regulated by endogenous inhibitors, the tissue inhibitors of metalloproteinases (TIMPs). Recent studies have indicated that endothelins and their receptor expression affects tissue remodeling and repair. Endothelins are rapidly produced by endothelial cells in response to tissue injury and they have potent vasoconstrictive properties. They also promote tissue remodeling through activation of resident connective tissue cells and controlling the production of MMPs and TIMPs by the activated cells. In this review we present the cross-talk between the endothelins and the MMP-TIMP system and their implications in controlling the normal and abnormal tissue remodeling.
Keywords: endothelin, matrix metalloproteinases, tissue inhibitors of metalloproteinases, connective tissue remodelling, extracellular matrix, scarring, fibrosis
Current Vascular Pharmacology
Title: Connective Tissue Remodeling: Cross-Talk between Endothelins and Matrix Metalloproteinases
Volume: 3 Issue: 4
Author(s): David Abraham, Markella Ponticos and Hideaki Nagase
Affiliation:
Keywords: endothelin, matrix metalloproteinases, tissue inhibitors of metalloproteinases, connective tissue remodelling, extracellular matrix, scarring, fibrosis
Abstract: Connective tissue remodeling is achieved by a complex process involving several cell types, a plethora of growth factors, cytokines, chemokines and turnover of extracellular matrix (ECM). The main enzymes that degrade ECM molecules are matrix metalloproteinases (MMPs) and their activities are regulated by endogenous inhibitors, the tissue inhibitors of metalloproteinases (TIMPs). Recent studies have indicated that endothelins and their receptor expression affects tissue remodeling and repair. Endothelins are rapidly produced by endothelial cells in response to tissue injury and they have potent vasoconstrictive properties. They also promote tissue remodeling through activation of resident connective tissue cells and controlling the production of MMPs and TIMPs by the activated cells. In this review we present the cross-talk between the endothelins and the MMP-TIMP system and their implications in controlling the normal and abnormal tissue remodeling.
Export Options
About this article
Cite this article as:
Abraham David, Ponticos Markella and Nagase Hideaki, Connective Tissue Remodeling: Cross-Talk between Endothelins and Matrix Metalloproteinases, Current Vascular Pharmacology 2005; 3 (4) . https://dx.doi.org/10.2174/157016105774329480
DOI https://dx.doi.org/10.2174/157016105774329480 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current Dendrimer Applications in Cancer Diagnosis and Therapy
Current Topics in Medicinal Chemistry Trabectedin (Yondelis®) as a Therapeutic Option in Gynecological Cancers: A Focus on its Mechanisms of Action, Clinical Activity and Genomic Predictors of Drug Response
Current Drug Targets Reversing Agents for ATP-Binding Cassette (ABC) Transporters: Application in Modulating Multidrug Resistance (MDR)
Current Medicinal Chemistry - Anti-Cancer Agents Anabolics in Osteoporosis: The Emerging Therapeutic Tool
Current Molecular Medicine Antiviral Properties of Quinolone-based Drugs
Current Drug Targets - Infectious Disorders Passive and Active Tumour Targeting with Nanocarriers
Current Drug Discovery Technologies Prospects for Plant-Derived Chemopreventive Agents Exhibiting Multiple Mechanisms of Action
Current Medicinal Chemistry - Anti-Cancer Agents Effects of Endocrine Disruptors on Developmental and Reproductive Functions
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Skin Cancers in Elderly Patients
Anti-Cancer Agents in Medicinal Chemistry The Physiological Basis and Nutritional Function of Alpha-ketoglutarate
Current Protein & Peptide Science Inhibitors of Cancer Stem Cells
Anti-Cancer Agents in Medicinal Chemistry Interleukin 2 in Cancer Therapy
Current Medicinal Chemistry Complex 3D Models to Study Drug Targeting of Invadopodia
Clinical Cancer Drugs Recent Advances in Small-Molecule HIV-1 Integrase Inhibitors
Current Medicinal Chemistry Heterocyclic Drug-polymer Conjugates for Cancer Targeted Drug Delivery
Anti-Cancer Agents in Medicinal Chemistry The Application of Photofrin II® as a Sensitizing Agent for Ionizing Radiation-A New Approach in Tumor Therapy?
Current Medicinal Chemistry AIDS Related Viruses, their Association with Leukemia, and Raf Signaling
Current HIV Research Anticancer Drugs Designed by Mother Nature: Ancient Drugs but Modern Targets
Current Pharmaceutical Design The Cell Wall-Associated Proteins in the Dimorphic Pathogenic Species of Paracoccidioides
Current Protein & Peptide Science A Review of Fish Lectins
Current Protein & Peptide Science